Tests ONC201 with atezolizumab in endometrial cancer linked to obesity
Tests two drugs, ONC201 and atezolizumab, in adults with advanced endometrial cancer.
Key facts
- Who runs it
- UNC Lineberger Comprehensive Cancer Center
- Where
- Chapel Hill, United StatesSee the site
- Trial code
- Registry title
- ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 58 people, planned
- Started
- 23 Oct 2023
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Atezolizumab
- ONC201
- Record updated
- 29 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with endometrial cancer that has spread or come back and has grown after earlier chemotherapy. It tests the safety of ONC201 with atezolizumab.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Endometrial cancer that has spread or come back, confirmed under the microscope. Types include endometrioid, carcinosarcoma, serous, clear cell, adeno-squamous and mixed. At least one measurable tumour is needed.
- Earlier treatment
- Scans must show the disease grew after at least 1 line of chemotherapy for spread disease, or within 12 months of finishing chemotherapy given after surgery.
Main reasons for not taking part
- Earlier treatment with ONC201
- Earlier immune checkpoint treatment, such as anti-CTLA-4 or anti PD-L1 antibodies, or CD137 agonists
- Another investigational drug or trial in the last 28 days
- Chemotherapy or radiotherapy in the last 4 weeks
- Immune-suppressing medicines such as corticosteroids in the last 2 weeks
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Ability to understand and willingness to sign a written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information
- Age ≥ 18 years at the time of consent
- ECOG Performance Status of 0, 1, or 2
- Histologically confirmed metastatic or recurrent EC (endometrioid, carcinosarcoma, serous, clear cell, adeno-squamous and mixed histologies)
- Subjects must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria
- Must have radiographic disease progression after at least 1 line of systemic cytotoxic therapy for metastatic disease or with progression within 12 months of completing adjuvant chemotherapy
- Life expectancy of at least 3 months
- Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 72 hours prior to initiating study treatment
Who cannot take part
- Prior treatment with ONC201
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including antiCTLA-4, and anti PD-L1 therapeutic antibodies
- Treatment with another investigational agent or participation in another clinical trial within the last 28 days prior to initiating protocol therapy
- Subjects who have had chemotherapy or radiotherapy within 4 weeks prior to study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to initiating protocol therapy
- Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of protocol therapy Subjects receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study
- Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of protocol therapy
- Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti TNF-agents) within 2 weeks prior to initiation
Other criteria
- In order to participate in this study a subject must meet all of the eligibility criteria outlined below
Where in United States
- Lineberger Comprehensive Cancer CenterChapel Hill, United StatesContact: Melisa Ramirez-PinedaTaking people
About the trial
What the trial wants to find out
Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity epidemic. Obese women with EC have a 6.3-fold increased risk of death from this disease, as compared to their non-obese counterparts. Patients with advanced/recurrent EC are unlikely to be cured by surgery, conventional chemotherapy (paclitaxel + carboplatin is the standard first-line treatment), radiation, or a combination of these. Thus, new treatments for EC are desperately needed as well as a better understanding of the impact of obesity on EC biology and treatment.
Read full original descriptionShow less
The purpose of this study is to test the safety of a combination of treatments, atezolizumab and ONC201, given based on body weight, to treat endometrial cancer. Using the combination of atezolizumab and ONC201, has not been approved by the Food and Drug Administration (FDA) for the treatment of endometrial cancer. This clinical trial will examine the treatment of atezolizumab + ONC201 in obese and non-obese subjects with metastatic/recurrent EC.
The 2 groups in the trial
- ObeseTreatment being tested
Subjects with BMI \> 30 kg/m2
Treatment: Atezolizumab and ONC201
- Non-ObeseTreatment being tested
Subjects with BMI ≤ 29.9 kg/m2
Treatment: Atezolizumab and ONC201
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
- Plain-language title
- Tests ONC201 with atezolizumab in endometrial cancer linked to obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 January 2026